Lumipulse^® G Mesothelin

Product benefits

• Excellent sensitivity: ≤ 0.1 nmol/L.

• Excellent precision: Typical total CV's: < 6.0%

• Wide dynamic range: 0.1 - 100 nmol/L

• 30-day calibration interval - no need to run a full calibration for just one sample

• Less hands on time

• Eliminates operator to operator issues associated with manual ELISA assays

• Faster time to result - improved patient care

Clinical background 

Malignant mesothelioma is an aggressive tumor with poor prognosis. 

Clinical symptoms are not specific and most patients are referred and diagnosed late in the course of the disease. 

A reliable histologic diagnosis of malignant mesothelioma can require performing multiple pleural biopsies, however many patients are not clinically able to undergo such invasive procedures. 

Therefore, in patients with malignant pleural infusions and a clinical suspicion of malignant mesothelioma, a tumor marker assay is useful for assisting diagnosis, evaluating prognosis and monitoring response to treatment.

Numerous studies ^{1 - 10} have shown the potential usefulness and utility of the SMRP assay to assist in the diagnosis of malignant mesothelioma. 

References   

1. Mesothelioma White Paper, DO

2. Pass, H.I. (2001) Malignant Pleural Mesothelioma: Surgical Roles and Novel Therapies. Clinical Lung Cancer 3: 102-117.

3. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-1616

4. Consensus Report (2000) International expert meeting on new advances in the radiology and screening of asbestos-related diseases.  Scand J work Environm Health, 26: 449-54

5. Bianchi, C., (2001) Asbestos exposure in Malignant Mesothelioma of the Pleura: A survey of 557 cases.  Industrial Health, 39: 161-167

6. Stayner, L., et al. (2013) The Worldwide Pandemic of Asbestos-Related Diseases.  Annu. Rev. Public Health.  34:4.1-4.12.

7. Bianchi, C, et al.  (2007) Malignant Mesothelioma:  Global Incidence and Relationship with Asbestos.  Industrial Health, 45: 379-387. 

8. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-1616

9. Cristaudo, et al.  (2011) Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma.  Journal of Thoracic Oncology, 6(9): 1587-1593. 

10. Hollevoet, K. et al.  (2012)  Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma:  An individual Patient Data Meta-Analysis.  Journal of Clinical Oncology, 30:1541-1549. 

See the LUMIPULSE G1200 working in this video: